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Abstract
Genome-wide association studies, DNA sequencing studies, and other genomic studies are finding
an increasing number of genetic variants associated with clinical phenotypes that may be useful in
developing diagnostic, preventive, and treatment strategies for individual patients. However, few
common variants have been integrated into routine clinical practice. The reasons for this are
several, but two of the most significant are limited evidence about the clinical implications of the
variants and a lack of a comprehensive knowledge base that captures genetic variants, their
phenotypic associations, and other pertinent phenotypic information that is openly accessible to
clinical groups attempting to interpret sequencing data. As the field of medicine begins to
incorporate genome-scale analysis into clinical care, approaches need to be developed for
collecting and characterizing data on the clinical implications of variants, developing consensus on
their actionability, and making this information available for clinical use. The National Human
Genome Research Institute (NHGRI) and the Wellcome Trust thus convened a workshop to
consider the processes and resources needed to: 1) identify clinically valid genetic variants; 2)
decide whether they are actionable and what the action should be; and 3) provide this information
for clinical use. This commentary outlines the key discussion points and recommendations from
the workshop.
Keywords
genomic medicine; clinical actionability; database; electronic health records (EHR);
pharmacogenomics; DNA sequencing
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Introduction
Genome-wide association studies (GWAS), DNA sequencing studies, and other genomic
studies are finding an increasing number of genetic variants associated with clinical
phenotypes that may be useful in developing diagnostic, preventive, and treatment strategies
for individual patients. Conceptually, one can view these genetic variants along a continuum
between common polymorphisms and rare or private mutations [Manolio et al., 2009]. This
range of allele frequencies has implications for the discovery of such variants in different
populations, the study of such variants with regard to their clinical implications, and the
detection and interpretation of specific variants in a given individual. The vast amount of
human medical genetics research conducted over the last few decades began primarily with
the discovery of mutations in genes responsible for Mendelian diseases. More recently this
research expanded to include the common variation associated with multifactorial
phenotypes discovered through GWAS [Hindorff et al., 2009]. Clinical genetic testing has
been used in a specialized clinical genetics setting for over fifty years, providing specific
molecular diagnoses for thousands of individuals with rare single gene and chromosomal
disorders. Somatic tumor variants are now increasingly assayed in order to target
chemotherapy [McLeod 2013] and germline pharmacogenomic variants are beginning to be
incorporated into routine clinical practice in certain scenarios [Relling and Klein, 2011].
However, despite an increasing number of characterized variants from GWAS studies, few
common variants have been integrated into routine clinical practice. The reasons for this are
several, but two of the most significant are limited evidence about the clinical implications
of the variants and a lack of a comprehensive knowledge base that captures genetic variants,
their phenotypic associations, and other pertinent clinically relevant information that is
openly accessible to clinical groups attempting to interpret sequencing data [Evans et al.
2011; Manolio et al., 2013].
Data on the clinical implications of genetic variants are currently contained in a patchwork
of non-standardized repositories maintained by individual scientists, academic institutions,
laboratories, government entities, and industry and are not easily accessible to health care
providers and health care systems. Making this information accessible and useful for clinical
care will require systematic collection, extraction, evaluation, and synthesis of these findings
followed by standardized representation of the information in queryable databases, along
with tools permitting user-defined filtering. It will be important to compile the available
evidence and develop consensus views from the clinical, genetics, and laboratory
communities on what variants are actionable and the clinical actions to be taken. This
information must then be made available to clinicians through clinical decision support tools
embedded in electronic health records (EHR) [Starren et al. 2013].
As the field of medicine begins to incorporate genome-scale analysis into clinical care,
approaches need to be developed for collecting and characterizing data on the clinical
implications of variants, developing consensus on their actionability, and making this
information available for clinical use. The National Human Genome Research Institute
(NHGRI) and the Wellcome Trust thus convened a workshop to consider the processes and
resources needed to: 1) identify clinically valid genetic variants; 2) decide whether they are
actionable and what the action should be; and 3) provide this information for clinical use.
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The following sections summarize the discussion and the workshop recommendations (see
Box 1).
Existing Genetic Variation Resources
Several existing resources provide some of the underlying data required to characterize
genetic variants along the evidence continuum (Table I). For example, dbSNP is a catalog of
short genetic variation, OMIM contains clinical descriptions and genetic variation primarily
related to Mendelian diseases, and the NHGRI Genome Wide Association Catalog curates
significant SNP-trait associations from genome-wide association studies. There are also
approximately 1,600 locus-specific databases that curate clinical information on specific
genes or diseases, although they vary in the types of data included and nomenclature
followed (http://www.centralmutations.org/Lsdb.php). The National Center for
Biotechnology Information (NCBI) has developed a new database, ClinVar (http://
www.ncbi.nlm.nih.gov/clinvar/), to provide a public archive of reports about the
relationships between human variants and phenotypes along with the supporting evidence
from attributed sources such as clinical research studies and case reports, specialized
databases, clinical practice guidelines, and peer-reviewed literature.
Challenges in synthesizing these existing data resources include incomplete or inaccurate
phenotypic data and a lack of standard terminologies, thus limiting interoperability.
Representatives from the relevant databases and resources, along with bioinformatics and
clinical experts, should work together to identify reasonable technical standards for
exchange and reporting of genetic variant and associated phenotypic and clinical data.
Interactions among existing databases should be maximized to ensure comparability and
avoid duplication. In addition, none of these resources are currently designed to interact with
EHR systems, meaning clinicians would have to access the information by interrupting their
clinical workflow—a known barrier to use [Ross, 2009]. Consideration needs to be given to
how such a resource would be utilized by clinicians and how to optimize that usage under
conditions when a patient's individual sequence (or relevant extracts from) is or is not
directly available to the clinician. EHR vendors should be convened with other relevant
organizations such as major health payers and regulatory agencies to address data
interoperability and viable approaches for integrating genomic information and actionable
variants into EHR systems. Some possible technical characteristics of such a system were
recently outlined and include maintaining separation of primary molecular observations
from the clinical interpretations of those data, support data compression of sequence data to
clinically manageable subsets, without losing the ability to produce a fully accurate copy of
the original sequence, and support both human-viewable and machine-readable formats to
facilitate implementation of clinical decision support rules [Masys et al., 2012]
Identifying Genetic Variants for Potential Clinical Action
In characterizing evidence about genes and specific genetic variants for clinical use, the
concepts of analytic validity (AV), clinical validity (CV), and clinical utility (CU) are in
broad use (Box 2). Out of the three concepts, defining CU and reaching consensus on what
constitutes sufficient evidence for CU is the most challenging. Perspectives on what patient
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outcomes are significant can be highly variable, ranging from outcomes associated with a
clear opportunity for medical intervention and medical benefit to opportunity for behavioral
change to information that can be used in reproductive decision making and life planning.
Evidence thresholds may need to be tailored to the cost, burden, and/or risk of proposed
interventions. This means that different groups, such as patients, clinicians, payers, hospital
systems, and government agencies may reach different conclusions about CU even after
reviewing the same evidence. In the case of rare diseases in which formal CU may be
difficult to assess, the diagnostic information can still guide management of the patient,
which is a type of clinical utility [Grosse et al., 2010]. The discussion of what evidence is
needed for CU frequently centers on whether a clinician should order a particular genetic
assay to make a diagnostic or therapeutic decision, and does not address the question of
what a clinician could or should do if that information were already available. The latter is
important to consider under several possible future scenarios; people may order their own
sequence from commercial vendors and then present their clinician with the findings for
interpretation or participation in a research orientated biobank may lead to extensive genetic
variants including sequence data being available and potentially actionable. The Clinical
Pharmacogenetic Implementation Consortium (http://www.pharmgkb.org/page/
cpicGeneDrugPairs) has created a set of pharmacogenetic guidelines based on this principle.
The concept of “personal utility” has been put forward as another facet of medical decision-
making regarding the use of genetic testing [Foster et al. 2009]. For example, the specific
genetic etiology of a rare disorder can have immense value to families regardless of the
ability to intervene in a particular condition. Similar “personal utility” might be derived
from more common genetic variation, such as APOE status and Alzheimer's disease risk
[Roberts et al. 2011] and other profiles of variants with small contributions to multifactorial
disease [Gollust et al., 2012], but this type of information is by definition highly context-
dependent and requires input from the patient regarding whether such information is desired.
An intermediate category between CV and CU has been termed clinical actionability (see
Figure 1). This can be applied to variants having either proven CU or evidence sufficient to
indicate how existing variant information could or should be used clinically though
insufficient to establish CU unequivocally [Berg et al,. 2011]. This concept of actionability
also allows flexibility for clinicians or even institutions to tailor their use of variant
information to a particular patient, clinical setting, or local standard of practice. However,
lack of clear clinical utility also means that an action taken in response to the finding of a
genetic variant may in fact have detrimental outcomes. Furthermore, the definition of
“actionable” can range from a broad inclusion of variants with possible “personal utility” to
a more narrow definition of variants that have well-established implications for the
management of the individual patient.
As a practical matter, the variants identified in an individual patient will fall into two broad
categories: “known” genetic variants that have been observed previously and “novel”
genetic variants that have not been observed before and may be unique to that individual or
private to his or her family members. With regard to “known” genetic variants, the existence
of prior information about these variants should in theory facilitate the annotation of their
clinical significance or lack thereof, whereas “novel” genetic variants may require quite
Ramos et al. Page 5
Am J Med Genet C Semin Med Genet. Author manuscript; available in PMC 2014 September 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
different methods for determining their clinical relevance. Many of the databases of known
genetic variants listed in Table I are primary data archives, and thus maintain experimental
results regarding genetic variants and their phenotypic correlations rather than curators'
interpretation of these data. However, numerous medical centers and research programs are
beginning to evaluate these databases and other pieces of information to explore the use of
such variants in clinical care, and many are developing approaches for identifying variants
to be assayed and the actions to be recommended when they are detected (see Table II for a
brief description of some of these programs and approaches). These groups are often
evaluating the same assays, reviewing the same literature, and assessing the same evidence.
In addition, efforts to identify variants relevant to drug response have been ongoing through
the National Institute of General Medical Sciences (NIGMS)-led Pharmacogenomics
Knowledge Base (PharmGKB) and Pharmacogenomics Research Network (PGRN) and
independent research groups such as Coriell's Pharmacogenomics Advisory Group. Unifying
these often isolated efforts and developing a consensus framework for evaluating existing
data might reduce duplication of effort and eventually speed adoption of actionable genetic
variants into clinical practice.
Although significant progress has been made identifying disease variant associations, a key
barrier to the identification of variants for clinical use is the lack of clinical translational
research beyond this initial identification of an association to assess the risks, costs, and
health benefits of utilizing genomic information in the practice of clinical medicine. The
importance of this problem was evident from an informal poll of our workshop attendees
showing little consensus on the appropriateness of using genetic variant information in a
variety of clinical scenarios and from the discordance among genetics experts asked to
assess the importance of returning specific secondary findings after clinical sequencing
[Green et al., 2012]. The 2011 NHGRI strategic plan [Green and Guyer, 2011] identifies the
need for funding clinical research to accelerate the pace of knowledge generation needed to
increase the clinical use of genetic information. Given the large number of variants that
currently have limited evidence of actionability, despite their clinical validity [Berg et al,
2011], clear pathways will need to be developed for providing the evidence to move them
into the actionable range or demonstrate definitively their lack of clinical utility. Again, a
critical component of that pathway is deposition of primary data in well-defined,
standardized formats to public databases. To support standardized assessment of information
about human variation, it is critical that both the primary data and the current interpretation
of those data be freely accessible. Processes and decision support tools can then be applied
to the existing data to identify which variants are clinically actionable and provide these
variants and supporting information for clinical use as appropriate.
In addition to devising a plan to accumulate evidence of actionability for known clinically
valid variants, additional effort must be dedicated to expand the set of current associations
beyond populations of European ancestry. There is a paucity of data on associations in non-
European ancestry populations. Differences in allele frequencies and linkage disequilibrium
patterns across ancestry groups (The International HapMap Consortium, 2005; Abecasis et
al., 2010; Altshuler et al., 2010], as well as major differences in disease burden and severity
[Ramos and Rotimi, 2009], make research in these under-studied populations a critical need.
Further, determining the effect of rare variants on gene function is essential to determining
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the clinical impact of these variants [Marian 2012]. This might be addressed by enhancing
communications between researchers who identify rare or unique variants in well-
phenotyped individuals and families and researchers with interests in the specific gene(s)
implicated in these conditions. Another critical group of stakeholders are the diagnostic
laboratories performing clinical molecular tests for rare disorders. These clinical laboratories
often hold a wealth of information about variants detected in specific genes and their
interpretation of the pathogenicity of those variants. Thus, development of data-sharing
models that protect patient privacy could enhance communication regarding the clinical
significance of genetic variants. This model was used to create the International Standards
for Cytogenomic Arrays (ISCA) Consortium database where multiple academic and
commercial laboratories contribute data on copy number variants (CNVs) and associated
phenotypes. To date data on over 32,000 patients has been collected allowing rapid
identification of novel CNVs associated with a range of disorders. Together, these efforts
would create a so-called ‘translational loop’, from bench to bedside and back again, as
described below.
Creating a Translation Loop for Genomic Medicine
To achieve more effective translation of genomic variant information into clinical practice
requires not only a ‘push’ to move evidence-based information generated in the laboratory
into the clinic, but the ability to ‘pull’ or extract information from clinical data systems to
assess the impact of implementation of that research on real world clinical outcomes and
effectiveness (see Figure 2). This assessment should lead to further research to validate or
expand evidence and, where appropriate, modify clinical practice, creating the translation
loop. To ensure this translation loop is successful requires the identification of novel
research approaches that may be purposed to answer specific clinical questions. As noted
above, the spectrum of genetic variation from common to rare (or private) variants will
dictate the approaches that can be used to determine the clinical significance and
actionability of different types of genetic variants. For example, pharmacogenomic alleles
that are part of the natural human population variation should be amenable to large
prospective studies that can formally assess the evidence for clinical utility such as that
being done by the Electronic Medical Records and Genomics pharmacogenomics project
(eMERGE-PGX) [Gottesman O et al., 2013]. Although randomized control trials have been
the standard in evaluating clinical effectiveness and should continue to be utilized to better
understand the impact of various aspects of genomic medicine, they can be time consuming
and expensive. In addition, the application of clinical trial results with their tight controls to
the complicated milieu of routine patient care is difficult [Hoes, 2009]. Other methodologies
that produce useful observational data need to be considered. The use of extant publicly
accessible data warehouses (such as was done for the Medco-Mayo warfarin effectiveness
study [Epstein, 2011] or data from consumer genomics companies are such approaches. In
order to take advantage of these data warehouses and other clinical data repositories, it is
important to develop systems that can retrieve information about defined outcomes of
interest from these sources and other transactional data warehouses (e.g. payer databases,
pharmacy databases). Information from these sources can be used to assess the use of a
given variant by clinician; identify individual and organizational factors that facilitate or
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impede the actual use of the variant; assess the effect on health behaviors, compliance, and
other medical outcomes from the patient perspective; estimate the effect on cost of care; and
compare decision-making algorithms to determine which are best for clinical use.
Often clinical implementation does not occur until practice guidelines have been developed
by leading professional organizations; therefore, movement through the translational loop
may be prompted by observational studies which facilitate the use of novel data in a real
world setting. Data from observational studies, rather than clinical trials, may then provide
both the data and impetus for large scale clinical implementation. Alternatively, these
approaches could be used as preliminary, low cost methods to identify potential signals that
could be prioritized for examination in more traditional research designs. Dissemination of
these novel research approaches would avoid each health care system having to create its
own specific algorithm or educational resources for the use of common genetic variants in
clinical care, allowing the organizations to focus on the processes needed to implement this
in clinical care. This approach could also allow the testing of various types of
implementation approaches to see which are more effective in the clinic, provided that such
studies are performed systematically and outcomes are rigorously measured. These types of
novel approaches are probably most applicable to common variants responsible for
pharmacogenomic traits and risk for multifactorial diseases.
Another benefit of a translation loop is the ability to more rapidly understand the prevalence
and clinical impact of rare variants that are expected to be identified in genes of interest as
next generation sequencing is increasingly deployed in clinical and research settings. This is
of particular importance if rare variants with high clinical impact are to be identified and
used to improve patient care. However, the assessment of rare variants in clinical medicine
may require different methods than those used to assess pharmacogenomic variants or
common risk factors for multifactorial diseases. There are two contexts in which rare
variants might be evaluated: 1) in the diagnostic evaluation of a person with a suspected
single gene disorder, and 2) as part of a collection of “incidental” or “secondary” findings
from a genome-scale sequencing assay. In the molecular diagnostic setting, the goal is to
identify the single variant or combination of variants that explains the patient's presenting
phenotype. In contrast to the diagnostic setting, where there is a substantial a priori
probability of a genetic etiology, rare variants identified as genomic incidental or secondary
findings are problematic because in the absence of a family history or phenotypic features,
the a priori probability that the individual is affected with a particular single gene disorder
caused by a given variant is very small. Thus, evidentiary standards may be different for rare
variants depending on the clinical context.
Disparate types of evidence are used to define whether a given rare variant is likely to
provide such an explanation for a patient's diagnosis, including the allele frequency in
control populations, the effect of the variant on the translated protein compared to the types
of changes that typically cause the disorder, in silico predictions that take into account
evolutionary conservation and protein structure, and family segregation studies. The final
element needed to close the translation loop is the capability to aggregate assertions made by
researchers and molecular diagnostic laboratories regarding the pathogenicity (or lack
thereof) for particular variants in order to provide updated knowledge in an efficient way to
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the central databases that store information on genotypes and phenotypes (such as those
identified in Table I.) A curated centralized database could then be accessed by molecular
diagnostic laboratories or electronic health records in order to annotate the clinical
significance of variants identified through genome-scale sequencing. Health systems could
then implement automated mechanisms for updating clinically actionable information such
that messages could be passed into EHRs for patients who carry this variant, including
notifying their clinician in specific situations based on context-sensitive rules [Aronson et
al., 2012].
Inherent in this translation loop is a blurring of boundaries between research and clinical
care. Current rules and regulations are not adequately explicit about this distinction, leading
to variable interpretations by institutional IRBs. This impedes the collaboration needed
among institutions to generate sufficient patient numbers to be confident of the impact of
variants on clinical care. The advanced notice of proposed rule-making for revision of the
Common Rule [http://www.hhs.gov/ohrp/humansubjects/anprm2011page.html] may impact
the ability to pursue this type of research. One aspect of this proposal is that written consent
for research use of any biospecimens collected for clinical purposes would be required. The
impact of current and proposed new policies on the use of genetic variants in clinical
practice will need to be studied. Exploration of these and other policy issues with institutions
responsible for the oversight of human subjects research such as the Office for Human
Research Protections (OHRP) / National Research Ethics Service (NRES) and their
international counterparts is needed to try to harmonize approaches to these types of studies.
Conclusions
GWAS, DNA sequencing studies, and other genomic studies are producing a profusion of
genetic variants that are or may be associated with clinical phenotypes. For each of these
variants it is important to determine population-specific frequencies; identify which variants
have clinical effects and characterize those effects; and follow variant carriers over time to
study natural history and measure the impact of clinical intervention that result from
knowledge of these variants. To minimize the risk of being overwhelmed by the number of
variants that need to be evaluated for potential clinical actionability, strategies to prioritize
investigation are needed. This prioritization should include an upfront assessment of the
likelihood of clinical value based on standardized frameworks such as the method proposed
by Berg et al [Berg et al., 2011]. The scalability of such prioritization will be challenging
because each variant will most likely need a detailed review of available evidence for
multiple clinical scenarios. [Fullerton, Wolf et al. 2012]. Classification of genes or variants
into such schema should be vetted by larger groups of experts and, ultimately, professional
societies can review these evidence syntheses to generate clinical practice guidelines on
which clinical decision support tools can be built. Speeding the adoption of actionable
genetic findings for use in clinical care first requires the development of a dynamic and
comprehensive resource of clinically relevant genetic variants. To meet this need, the
NHGRI issued a funding opportunity titled ‘Clinically Relevant Genetic Variants Resource
(CRVR): A Unified Approach for Identifying Genetic Variants for Clinical Use (U01)
(http://grants.nih.gov/grants/guide/rfa-files/rfa-hg-12-016.html). CRVR has since evolved
into the Clinical Genome Resource - a collaboration between CRVR grantees and the
Ramos et al. Page 9
Am J Med Genet C Semin Med Genet. Author manuscript; available in PMC 2014 September 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
International Collaboration for Clinical Genomics (ICCG formerly the ISCA referenced
above) to develop a pipeline for the submission by clinical laboratories of sequence variants
and related data to a central database (ClinVar), curate these variants with clinical and
functional data, develop a consensus process to bin genes and variants into categories of
clinical actionability, identify clinically relevant variants for consideration for clinical use,
and systematically disseminate this information including creating a resource that is
compatible with standards based electronic health record systems. Engaging the numerous
individual research efforts and relevant stakeholders including genetics researchers,
bioinformaticians, clinicians and medical institutions, professional societies, and regulatory
agencies, is paramount for shaping such a comprehensive and useful resource.
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Box 1. Characterizing and Displaying Genetic Variants for Clinical Action
Workshop Recommendations
Existing Genetic Variation Resources
• Hold a workshop or convene a working group to identify reasonable technical
standards for exchange of genetic variant and clinical data to maximize
exchange of among existing databases.
• Coordinate with US and UK agencies, such as Agency for Healthcare Research
and Quality (AHRQ), the Office of the National Coordinator for Health
Information Technology (ONC), Department of Veterans Affairs (DVA),
National Health Service (NHS), commercial electronic health record (EHR)
vendors, and other relevant organizations to address data interoperability and
viable approaches for integration of genomic information and actionable
variants into a variety of EHR systems.
• Facilitate the clinical annotation of genes and germline and somatic variants in
relation to specific traits (including specificity, sensitivity, prevalence, positive
and negative predictive values, and penetrance). Capture of penetrance data
from exome chip studies may be a good opportunity to capture information on
the “most common of the rare” variants.
• Ensure that 1) ClinVar and similar resources capture genetic variants of
unknown significance (VUS) and isolated reports of variant – condition
associations identified through clinical sequencing projects, and 2) computer
programs are developed to enable clinical sequencing labs to efficiently transmit
data to such resources.
Identifying Genetic Variants for Potential Clinical Action
• Support and expand research to determine clinical validity and utility/
actionability of SNP and structural genetic variants.
• Design studies to ensure that clinically valid variants for which actionability is
unknown are appropriately stratified and have identified research pathways for
determining actionability.
• Ensure that studies of gene-disease and gene-drug associations in diverse
populations are funded.
• Support functional and other follow-up studies on novel variants found in
specific genes with known utility (e.g., determine the consequence of every
BRCA1 variant) to generate data to support better interpretation of variants of
uncertain significance.
• Explore mechanisms to facilitate communication between labs studying specific
genes with potentially clinically relevant variants and researchers and clinicians
with family, phenotype and other clinical information willing to partner to study
the function of the genes and variants.
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• Maximize interactions among epidemiologists, bioinformaticians, and genomic
scientists to facilitate obtaining needed information on clinical validity and
utility. For example, develop training programs that bring these three disciplines
together to tackle specific aspects of the pipeline needed to identify actionable
variants and move them into the clinic.
• Serve as a “convener” in conjunction with other NIH Institutes and Centers,
professional organizations, and other groups to build consensus, prioritize and
publicize recommendations regarding clinical validity and utility/actionability.
Creating a Translation Loop for Genomic Medicine
• Create and support a coordinated resource to extend Ensembl, ClinVar, and
other databases for use in clinical care by providing relevant phenotype
information, other clinical annotation, and suggestions regarding clinical utility/
actionability. Such a resource could help bridge the gap between researchers and
primary care clinicians, who will need user-friendly clinical support tools and/or
an EHR integration layer to readily utilize these data in clinical care.
• Collaborate with data warehouses (e.g. Medco) on large-scale studies to better
evaluate outcomes of specific uses of genomic variants in clinical care. Develop
a process to identify research questions that could be answered using data
warehouses.
• Consider supporting competitions that promote development of algorithms for
interpreting genomic variants and compare algorithm performance, such as the
Critical Assessment of Genome Interpretation (CAGI; http://
genomeinterpretation.org/) effort.
• Encourage the dissemination of decision support logic and interpretive tools,
including making a publicly available library, to enable diverse EHR systems to
use the same logic and tools when developing clinical decision support tools.
• Develop and test innovative genetic education tools for providers specifically
focused around the appropriate use of genomic variants.
• Develop approaches for long-term follow-up of patients with rare variants of
interest to better understand the relationship of these variants to disease and
other phenotypes, leveraging existing resources with healthcare systems (e.g.,
payer information, NHS records).
• Catalyze discussion with the US Office for Human Research Protections
(OHRP) and the UK National Research Ethics Service (NRES) regarding
institutional review board guidance on boundaries and synergy between clinical
care and research. Conduct policy analyses to better understand the perspectives
of relevant organizations (e.g., FDA, CMS, NICE, UKGTN and professional
organizations such as ACMG, CAP, and AMP) regarding using genetic variant
information to inform clinical care.
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Box 2. Definitions*
Analytic Validity (AV) How accurately and reliably the test measures the genotype of
interest.
Clinical Validity (CV) How consistently and accurately the test detects or predicts the
intermediate or final outcomes of interest.
Clinical Utility (CU) How likely the test is to significantly improve patient outcomes.
*as defined by the CDC's Office of Public Health Genomics (OPHG) ACCE Model
Process for Evaluating Genetic Tests (http://www.cdc.gov/genomics/gtesting/ACCE/
index.htm).
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Figure 1.
Schematic diagram showing overlap of clinical validity (outer boundary, containing all
genetic variants with a valid clinical association), clinical utility (inner white circle), and the
boundaries of clinical actionability (shaded circles). Depending on the criteria used to define
“actionability” (depicted by double arrows) the boundaries could be more or less inclusive
(dashed circles). In this scheme, variants with clinical utility are a subset of all clinically
actionable variants.
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Figure 2.
A framework for a translational loop in genomic medicine, with green representing the first
phase of translation and blue representing the second phase of translation), with a feedback
loop to basic science discoveries. Adapted with permission from M. Khoury [Khoury et al.,
2012].
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Table I
Commonly used databases and resources that relate genotype to human phenotypes and
disease
Database/Resource Brief Description Main Purpose URL
ClinVar Aggregates information about sequence
variation and its relationship to human
health
Provide assertions
of variation-
phenotype
relationships
http://www.ncbi.nlm.nih.gov/clinvar/
dbSNP Database of short genetic variation Archive germline
variation (both
polymorphism and
rare mutation).
Provides alleles,
genotypes and their
respective
frequencies by
population
http://www.ncbi.nlm.nih.gov/snp
dbVaR Database of genomic structural variation Archive studies of
structural variation
and their
interpretation
http://www.ncbi.nlm.nih.gov/dbvar/
Ensembl Genome databases for vertebrates and other
eukaryotic species,
Develop a software
system which
produces and
maintains automatic
annotation on
selected eukaryotic
genomes
www.ensembl.org
Human Gene Mutation
Database
Database of the first example of all
mutations causing or associated with human
inherited disease, plus disease-associated/
functional polymorphisms reported in the
literature
Collate published
gene lesions
responsible for
human inherited
disease and provide
information of
practical diagnostic
importance to
genetics
professionals
http://www.hgmd.cf.ac.uk/ac/index.php
The International
Standards for
Cytogenomic Arrays
(ISCA) Consortium
Central repository for cytogenomic array
data generated in clinical testing
laboratories.
Useful for
classifying copy
number variants of
uncertain clinical
significance
https://www.iscaconsortium.org/
NHGRI GWAS Catalog Compendium of SNP-trait associations
gleaned from published GWAS studies
Provide a catalog of
significant findings
from all published
GWAS studies to
facilitate
prioritization,
replication, and
follow-up
http://www.genome.gov/GWAStudies/
NIH Genetic Testing
Registry (GTR)
Uses laboratory-reported data to provide
information about genetic tests for inherited
genetic variations. Also reports disease- and
gene-specific information integrated from
NCBI's databases
Provide a catalogue
of genetic tests in
clinical use for
clinicians. While
most information
will be at the gene
level, tests for single
variants will be
http://www.ncbi.nlm.nih.gov/gtr/
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Database/Resource Brief Description Main Purpose URL
included. Assertions
of AV, CV, and CU
are made by test
submitters. NCBI
assembles practice
guidelines
OMIM Compendium of human genes and genetic
phenotypes
Provide physicians
and other
professionals with
full-text, referenced
overviews for
Mendelian disorders
and > 12,000 genes
http://www.omim.org/
PharmGKB Pharmacogenomics knowledge resource Provide information
about the impact of
genetic variation on
drug response for
clinicians and
researchers
http://www.pharmgkb.org/
PheGenI Merges NHGRI GWAS catalog data with
data-bases housed at the NCBI including
Gene, dbGaP, OMIM, GTEx and dbSNP
Facilitate
prioritization of
GWAS variants to
follow up, study
design
considerations, and
generation of
biological
hypotheses
http://www.ncbi.nlm.nih.gov/gap/PheGenI
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Table II
Current approaches for identifying genomic variants for potential clinical use
Program Brief Description of Approach
Coriell Personalized
Medicine Collaborative,
CPMC®
Longitudinal study examining impact of potentially actionable genomic results for common complex
diseases and drug response. Uses two external oversight bodies, Informed Cohort Oversight Board (Complex
Diseases) and Pharmacogenomics Advisory Group (drug response) to determine what variants will be
returned to study participants (Stack, Gharani et al. 2011)
Clinical Genome Resource
(ClinGen)
Developing a pipeline for the submission by clinical laboratories of sequence variants and related data to
ClinVar, curating these variants with clinical and functional data, developing a consensus process to bin
genes and variants into categories of clinical actionability, and systematically disseminating this information.
Electronic Medical Records
and Genomics Network
(eMERGE) Return of Results
Working Group
Recommended that Klinefelter, Turner, and homozygosity for Factor V Leiden be considered for return to
research participants.(Fullerton, Wolf et al. 2012) The current focus is to define an initial set of variants that
are potentially useful in clinical practice for purposes such as assessment of genetic risk for complex
disorders or selection or dosing of drugs. This initial set will focus on common disease risk variants and
pharmacogenomic variants for which eMERGE sites expect to have data.
International Collaboration
for Clinical Genomics
(ICCG)
Participating in the ClinGen program. Curation and evidence-based review of structural and sequence-level
variant data deposited within ClinVar to assign consensus annotation of variants with regard to their clinical
significance (e.g., “pathogenic”, “benign”, etc.) and standardize clinical interpretations.
Clinical Pharmacogenetics
Implementation Consortium,
CPIC
Expert consensus of CPIC members. Consensus results in a clinical algorithm that defines the clinical
context and defines the information required and provides a specific clinical recommendation. Published in
peer-review literature. Focus is on how available genetic test results should be used to optimize drug therapy,
rather than whether tests should be ordered. (Relling and Klein 2011) Recommendations include CYP2C9,
VKORC1 for warfarin dosing; CYP2C19 for clopidogrel therapy; TPMT and thiopurine dosing; SLCO1B1
and simvastatin; CYP2D6 and codeine.
Evaluation of Genomic
Applications in Practice and
Prevention, EGAPP Working
Group
Systematic evidence review with a focus on clinical utility followed by synthesis of evidence and
development of recommendation statement (Teutsch, Bradley et al. 2009) Evidence reviews and
recommendation statements do provide information about the clinical context and how the variant
information is proposed to be used that could inform clinical action to be taken.
NHGRI Clinical Sequencing
Program (CSER)'s
Actionable Variants and
Return of Results Working
Groups
The Actionable Variants WG coordinate approaches to defining and binning genetic variants potentially
useful for clinical purposes; share and review external resources for similar purposes. Discuss emerging
issues and develop standards related to returning results to study participants (including incidental findings,
where determined to be appropriate).<break/>The Return of Results WG Analyze the relevant normative and
clinical issues, including such issues as whether or when there exists an ethical duty to return results, what
are the appropriate normative and clinical criteria for determining whether results should be returned, the
meaning of “actionability” and whether “actionability,” should be the relevant standard for determining
which results are returnable.
FDA Table of
Pharmacogenomic
Biomarkers in Drug Labels
FDA-approved drugs with pharmacogenomic information in their labels. Some, but not all, of the labels
include specific actions to be taken based on genetic information (http://www.fda.gov/drugs/scienceresearch/
%20researchareas/pharmacogenetics/ucm083378.htm)
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